Timeline – Lead Plaintiff Motion and What Typically Follows in a Class‑Action Case
| Event | Date/Deadline (as given in the filing) | What Happens Next (general class‑action practice) |
|---|---|---|
| Class‑Period Purchases | May 7 – July 28 2025 (inclusive) | Investors who bought Novo Nordisk (NYSE: NVO) stock during this window are the “potential class members.” |
| Filing of the Class‑Action Complaint | Early August 2025 (the press release was issued August 7, 2025) | The complaint alleges securities‑fraud violations and seeks damages on behalf of all class members. |
| Lead‑Plaintiff Motion Deadline | September 30 2025 (the last day to file a motion to be appointed lead plaintiff) | Any class member (or a group of members) who believes they are best suited to lead the case can submit a motion. The motion must explain why the movant has the “qualifying stake,” “adequate representation,” and “ability to protect the interests” of the class. |
| Court Review of Lead‑Plaintiff Motions | Early‑mid October 2025 (typically 2‑4 weeks after the deadline) | The judge (or the court’s appointing officer) will review all motions, consider factors such as the size of the loss, the plaintiff’s credibility, and the ability to fund the litigation, and may hold a brief hearing. |
| Appointment of Lead Plaintiff | Mid‑October 2025 – early November 2025 (often within 30 days after the deadline)** | The court issues an order naming the lead plaintiff and may also appoint a lead counsel. If multiple motions are filed, the court may select the strongest or even appoint co‑lead plaintiffs. |
| Case Management Conference / Scheduling Order | Late November 2025 – January 2026 | After the lead plaintiff is appointed, the court typically holds a case‑management conference to set a schedule for discovery, motion practice, and any preliminary settlement talks. The scheduling order will include key dates such as: • Initial disclosures (usually 30‑45 days after the conference) • Discovery plan (often 6‑12 months of document production, depositions, interrogatories) • Motions deadline (e.g., summary‑judgment motions may be due 12‑18 months after filing) |
| Discovery Phase | Early 2026 – Mid‑2027 (approx.) | Both sides exchange evidence, take depositions of Novo Nordisk officials, and may file disputes that the court will resolve. This phase can last anywhere from 12‑18 months, depending on the complexity of the alleged fraud. |
| Pre‑Trial Motions / Settlement Negotiations | Mid‑2027 – Late 2027 | Parties often file motion for class certification, motion to dismiss, and/or summary‑judgment motions. Settlement talks usually intensify after discovery is largely complete; many securities‑fraud class actions settle before trial. |
| Potential Trial | Late 2027 – 2028 (if no settlement) | If the case proceeds to trial, the court will set a trial date. A securities‑fraud trial can span several weeks to a few months, after which a verdict (or judgment) is entered. |
| Resolution (Settlement or Judgment) | 2028‑2029 (typical range) | Most securities‑fraud class actions are resolved by settlement. If a settlement is reached, the court will hold a fairness hearing and issue a final approval order. If a judgment is entered, any appeals will add additional months to the timeline. |
Key Take‑aways for Investors
Lead‑Plaintiff Motion Deadline is Sept 30 2025.
- If you (or a group you belong to) suffered a loss and want to steer the litigation, you must submit your motion on or before this date.
After the Deadline, the Court Decides Who Leads.
- The judge will evaluate all motions and appoint the plaintiff (or co‑plaintiffs) who best represents the class.
From Appointment to Resolution Takes Several Years.
- Even after a lead plaintiff is named, the case will move through discovery, motions, possible settlement negotiations, and—if it goes that far—a trial. Realistically, the full lifecycle (from filing in August 2025 to final resolution) is approximately 3‑4 years, with most cases settling within that window.
What Happens If You Miss the Motion Deadline?
- You can still be part of the class (receive any eventual settlement or judgment), but you won’t have the opportunity to influence strategy as the lead plaintiff.
Practical Steps for Potential Class Members
| Step | When | Action |
|---|---|---|
| Monitor Communications | Ongoing, starting now | Keep an eye on notices from Glancy Prongay & Murray or the court. They will announce when the lead‑plaintiff motion filing portal opens and any required forms. |
| Assess Eligibility | Immediately | Verify that you bought Novo Nordisk shares (or acquired them in another manner) between May 7 – July 28 2025 and suffered a loss attributable to the alleged fraud. |
| Prepare Motion (if interested) | By mid‑September 2025 | Gather documentation of purchase dates, amounts, and loss calculations; draft a brief explaining why you’re the best lead plaintiff (e.g., largest loss, credibility, ability to finance the case). |
| Submit Motion | No later than Sept 30 2025 | Follow the filing instructions (usually electronic submission via the court’s e‑filing system). Keep proof of filing. |
| Stay Informed After Deadline | Oct 2025 onward | Watch for the court’s order appointing the lead plaintiff and for any case‑management conferences that set the broader litigation schedule. |
Bottom line: The lead‑plaintiff motion deadline is September 30 2025. After that, the court will appoint the lead plaintiff (usually within a few weeks), and the case will move through the usual class‑action timeline—discovery, motions, possible settlement, and, if necessary, trial—typically concluding 3‑4 years after the initial filing. If you are a potential class member and wish to influence the case, ensure your motion is filed by the September 30 deadline.
Other Questions About This News
How will the filing of this securities fraud class action affect Novo Nordisk's stock price in the short term?
How does this legal development compare to recent class actions involving other pharmaceutical companies?
How might the class action impact Novo Nordics's reputation and future earnings forecasts?
What is the likely market reaction from institutional investors and analysts to this news?
What are the potential upside or downside scenarios for Novo Nordisk based on possible outcomes of the case?
Are there any insider trading activities or unusual volume patterns surrounding the announcement?
Could this lawsuit trigger further investigations or regulatory actions against Novo Nordisk?
What specific allegations are being made against Novo Nordisk in the class action lawsuit?
What is the estimated potential liability or settlement amount for Novo Nordisk in this case?